Application of syringaresinol in preparation of medicines for treating depression

A technology for syringaresinol and depression, which can be used in drug combinations, active ingredients of heterocyclic compounds, nervous system diseases, etc., and can solve problems such as difficulty in promotion, toxic side effects, and influence on daily life.
CN110179784AInactive Publication Date: 2019-08-30THE KEY LAB OF CHEM FOR NATURAL PROD OF GUIZHOU PROVINCE & CHINESE ACADEMY OF SCI
3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Applications(China)
Current Assignee / Owner
THE KEY LAB OF CHEM FOR NATURAL PROD OF GUIZHOU PROVINCE & CHINESE ACADEMY OF SCI
Publication Date
2019-08-30
Estimated Expiration
Not applicable Β· inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention discloses an application of syringaresinol in preparation of medicines for treating depression. When concentration of activity-screened syringaresinol is 12.5 [mu]M, the syringaresinol has an obvious protection activity against SH-SY5Y cell injury induced by sodium glutamate, facilitates further pharmacological and clinical research, and creates conditions for developing themedicines for treating depression.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the application of syringaresin, in particular to the application of syringaresin in preparing medicine for treating depression. Background technique

[0002] Nervous system diseases are diseases that occur in the central nervous system, peripheral nervous system, and autonomic nervous system and are mainly manifested by sensory, motor, consciousness, and autonomic dysfunction, such as Alzheimer's disease, Parkinson's disease, depression, etc. It has brought great influence to patients' life and work. Among them, depression is a group of chronic syndromes with high recurrence rate and serious harm to human physical and mental health. At present, Western medicine for the treatment of depression mainly focuses on the first-generation tricyclic depressants and monoamine oxidase inhibitors and the second-generation serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors, such as fluoxetine, venlafaxine,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More